Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
|Videos|March 8, 2022
Dr. Rogers discusses FDA approval of InterStim X system
Author(s)Urology Times staff
The device is indicated for overactive bladder, chronic fecal incontinence, and non-obstructive urinary retention.
Advertisement
In this video, Alexandra Rogers, MD, comments on the recent FDA approval of the InterStim X system. Rogers is a urologist in Boulder, Colorado.
Advertisement
Related to this article
Bladder symptoms during IVF often reflect hormonal and pelvic floor changes, not infection, according to Aleece Fosnight, MSPAS, PA-C.
Sri Sivalingam, MD, discusses how suction-based technologies are improving stone clearance and raising expectations for ureteroscopic stone treatment.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Mark D. Tyson, II, MD, MPH, reviews emerging bladder-sparing therapies for NMIBC, highlighting cretostimogene data, treatment sequencing, and the need for comparative trials.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants fast track designation to VIR-5500 for mCRPC
2
FDA grants 510(k) clearance to OpenFlo urinary catheter
3
Variation in PSMA PET Adoption for Prostate Cancer Care
4
Prostate Cancer Case Review: Biochemical Recurrence and a Rib Lesion
5